Indaptus Therapeutics, Inc.
INDP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $7,251 | $7,622 | $6,325 | $2,523 |
| G&A Expenses | $8,013 | $8,757 | $8,586 | $5,206 |
| SG&A Expenses | $8,115 | $8,757 | $8,586 | $5,206 |
| Sales & Mktg Exp. | $102 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $15,366 | $16,378 | $14,911 | $7,729 |
| Operating Income | -$15,366 | -$16,378 | -$14,911 | -$7,729 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $344 | $955 | $588 | $18 |
| Pre-Tax Income | -$15,022 | -$15,423 | -$14,323 | -$7,711 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$15,022 | -$15,423 | -$14,323 | -$7,711 |
| % Margin | – | – | – | – |
| EPS | -1.61 | -1.84 | -1.73 | -1.89 |
| % Growth | 12.5% | -6.4% | 8.5% | – |
| EPS Diluted | -1.61 | -1.84 | -1.73 | -1.89 |
| Weighted Avg Shares Out | 9,356 | 8,401 | 8,262 | 4,091 |
| Weighted Avg Shares Out Dil | 9,356 | 8,401 | 8,262 | 4,091 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $588 | $18 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $2 | $1 |
| EBITDA | -$15,365 | -$16,377 | -$14,909 | -$7,728 |
| % Margin | – | – | – | – |